Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market.
Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.
CMO Group 22.5p £16.2m (CMO.L)
The UK online-only retailer of building materials, provides a trading update for the half year to 30 June 2023. The Board expects EBITDA to be in line with market expectations for the year of £2.5m, albeit with sales lower at c.£80m. Sales in the first half of £36.9m represent a one year like-for-like decline of 12%, 15% up on pre-Covid like-for-like and representing an increase of 57% on a four-year view. Net cash at the end of the period was £1.0m, a reduction since the year end of £0.4m. Cash on the balance sheet was £4.7m at the period end (FY2022 £6.2m), with drawn facilities of £3.7m (Y/E 2022 £4.6m). As previously announced, the Group have laid out key strategic priorities for 2023 to reduce cost, improve margins, address carriage costs and adapt to current slower sales growth. The Group expects to improve profitability in the second half and deliver full year results in line with expectations.
Coro Energy 0.265p £7.5m (CORO.L)
The South East Asian energy company with a natural gas and clean energy portfolio, announces that it has received an indicative funding proposal and is now in advanced talks with Capton Energy regarding possible co-investment solutions for Coro's Vietnamese rooftop solar projects. Capton Energy, based in Dubai, is a joint venture between Siemens Financial Services and Desert Technologies. The platform is focused on Energy Transition infrastructure in Africa, the Middle East, and Asia. The funding proposal received is for Capton to buy into Coro's current Vietnamese solar projects and provide investment into Coro's project pipeline of up to 50 megawatts. Coro has committed to a four-month period of exclusivity for the parties to conclude the transaction.
Global Invacom Group 4.85p £5.6m (GINV.L)
The global provider of satellite communications equipment and electronics, provides a trading update for the six months ended 30 June 2023. The Group expects to record a net loss of approximately US$2.1m for 1H FY2023 (H1 2022: net loss of US$3.3m). Group revenue is expected to be approximately US$31.3m versus US$37.4m in H1 2022. Despite the decrease in revenue, gross profit has increased to US$8.3m (H1 2022: US$7.4m) with gross profit margin increasing to 26.5% (1H 2022: 19.7%), due to increased business focus on product mix. The Group’s efficiency initiatives at its US manufacturing facilities, combined with actions from the ongoing strategic review, have contributed to improved profit margins and reduced losses.
Horizonte Minerals 157.5p £424.4m (HZM.L)
The nickel company developing two Tier 1 assets in Brazil, reports that it is continuing to make good progress on the construction of its 100%-owned Araguaia Nickel Project Line 1, with first metal production on-schedule for Q1 2024. Approximately 65% of the overall construction of Araguaia was completed as of 30 June 2023. Several major milestones were achieved during the quarter including the delivery of the Rotary Kiln and commencement of ore mining. US$329m has been spent on the Araguaia construction out of the budgeted capital requirement of US$537m. Araguaia Nickel Project Line 2 Feasibility Study (FS), which aims to double nickel production from 14,500 tonnes per annum to 29,000 tonnes per annum, is to be published later this year. Liquidity and funding sources of US$344m as of 30 June 2023.
LifeSafe Holdings 40.5p £8.7m (LIFS.L)
The fire safety technology business with innovative fire extinguishing fluids and fire safety products, announces its intention to raise gross proceeds of up to, in aggregate, approximately £0.94m by means of a placing of new Ordinary Shares at a price of 37 pence per share. The Placing Price represents a discount of approximately 8.6% to the Closing Price on 2 August 2023. The Placing is being conducted in two tranches with the initial tranche of Placing Shares being issued under the Company's pre-existing share capital authorities and the issue of the second tranche of the Placing Shares being subject to the requisite shareholder approval at the forthcoming General Meeting. In addition, the Company is proposing to raise £0.14m a Subscription and £0.25m via a retail offer, both at the Placing price. The net proceeds of the Fundraising will be utilised to procure stock for H2 2023 and for general working capital purposes.
Omega Diagnostics Group 2.5p £5.9m (ODX.L)
The specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces its audited results for the year ended 31 March 2023. Despite sales growing by c.80% in the UK, overall revenues decreased by 12% to £7.5m (2022: £8.5m). Order intake was up by 71% to £2.4m (2022: £1.4m) over the prior year due to new installations and an increase in educating consumers and driving awareness. Operating loss (continuing operations) was £3.2m (2022: £0.9m) and Adjusted EBITDA (continuing operations) was £2.0m (2022: £0.2m). Cash balance was £5.0m as at 31 March 2023. During the period, the Company disposed of the CD4 business and launched MyHealthTracker digital app. This year has seen the final steps in the withdrawal from the Global Heath business and the full relocation to the Health and Nutrition manufacturing site in Ely, Cambridgeshire. The year ahead will be the first full year with the focus on the Health and Nutrition business.
One Heritage Group* 29p £11.2m (OHG.L)
The UK-based residential developer, development manager and property manager focused on the North of England, announces that its parent company and majority shareholder One Heritage Property Development Ltd (OHPD) has extended its support and increased its £12.3m debt facility by £1.7m to £14.0m. The extension has been made at the same interest rate of 7% and a repayment date of 31 December 2024.
Polarean Imaging 16.5p £35.3m (POLX.L)
The commercial-stage medical device leader in advanced MRI scanning of the lungs, announces it has received 510K clearance from the U.S. Food and Drug Administration (FDA) for the Company’s specialised MRI chest coil to now include Philips 3.0T MRI scanners for the visualisation of the Xenon-129 (129Xe) nuclei. The Polarean XENOVIEW™ 3.0T Chest Coil is a flexible, single channel, transmit-receive RF coil tuned to image 129Xe nuclei while a patient is positioned inside a multinuclei-capable MRI scanner. The XENOVIEW Chest Coil is to be used in conjunction with compatible 3.0T MRI scanners and approved hyperpolarised 129Xe for oral inhalation for the evaluation of lung ventilation. The addition of the new Philips configuration does not affect the intended use of the device; the safety and effectiveness has been confirmed with testing.
Sareum Holdings* 100p £68.1m (SAR.L)
The clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune diseases and cancer, announces that it has agreed terms on an Equity Prepayment Facility of up to £5m with RiverFort Global Opportunities PCC Ltd, with an initial deposit of £2m, expected to be received by the Company on 4th August 2023, net of associated costs. The Company intends to use the Facility, if fully drawn, together with the receipt of anticipated tax credits to the amount of £1.6m, to complete the Phase 1a/b clinical development of its lead candidate SDC-1801, which is expected to be a primary catalyst for driving shareholder value, and for general working capital to Q4 2024. The Company expects to provide a further update on Part 1 of Phase 1a trial of SDC-1801 once initial safety and pharmacokinetic data observed in the single ascending dose part of the study provide sufficient support for progression to Part 2 of the study, the multiple ascending dose, expected in H2 2023.
ScS Group 167.75p £57.0m (SCS.L)
One of the UK's largest retailers of upholstered furniture and floorings, provides a trading update for the 52 weeks ended 29 July 2023. The Group expects to report full year profit in line with market expectations, driven by effective cost management and improved trading in the second half of the year. Following ScS’s updated brand and strategy, like-for-like order growth of 6.0% from weeks 34 to 52 building on the 5.7% previously announced for weeks 27 to 33. As a result of this growth, following a challenging first quarter, order intake for the full year was in line with FY22. The Group's financial position remains robust, with cash at 29 July 2023 of £69.5m and no debt. Despite challenging conditions, ScS continues to expect to grow its market share while selectively investing in store and other strategic growth opportunities.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
